REFERENCES
1. Rinella ME, Lazarus JV, Ratziu V, et al. ; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-86.
3. Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-associated steatotic liver disease: update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024;79:1212-9.
4. Powell EE. A new treatment and updated clinical practice guidelines for MASLD. Nat Rev Gastroenterol Hepatol. 2025;22:88-9.
5. Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71:793-801.
6. Grander C, Grabherr F, Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovasc Res. 2023;119:1787-98.
7. Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J Obes Metab Syndr. 2023;32:197-213.
8. Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up. Hepatology. 2015;61:1547-54.
9. Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158:1611-25.e12.
10. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis. Hepatology. 2017;65:1557-65.
11. Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28:528-62.
12. Hagström H, Shang Y, Hegmar H, Nasr P. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol. 2024;9:944-56.
13. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335-47.
14. Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022;10:284-96.
15. Goh GB, Pan A, Chow WC, Yuan JM, Koh WP. Association between diabetes mellitus and cirrhosis mortality: the Singapore Chinese Health Study. Liver Int. 2017;37:251-8.
16. Sanyal AJ, Van Natta ML, Clark J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385:1559-69.
17. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367-78.e5.
18. Friedman SL, Neuschwander-tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908-22.
19. Kanwal F, Shubrook JH, Adams LA, et al. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2021;161:1657-69.
20. Chen VL, Morgan TR, Rotman Y, et al. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology. 2025;81:312-20.
21. Bansal MB, Patton H, Morgan TR, Carr RM, Dranoff JA, Allen AM. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology. 2026;83:1326-40.
22. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184:2537-64.
23. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology. 2008;134:424-31.
24. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038-48.
26. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183-92.
27. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42:987-1000.
28. Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. Hepatology. 2008;48:670-8.
29. Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279:32345-53.
30. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature. 2002;420:333-6.
31. Petersen MC, Madiraju AK, Gassaway BM, et al. Insulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance. J Clin Invest. 2016;126:4361-71.
32. Petersen MC, Shulman GI. Roles of diacylglycerols and ceramides in hepatic insulin resistance. Trends Pharmacol Sci. 2017;38:649-65.
33. Czaja MJ. JNK regulation of hepatic manifestations of the metabolic syndrome. Trends in Endocrinol Metab. 2010;21:707-13.
34. Bednarz K, Kowalczyk K, Cwynar M, et al. The role of Glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome. Int J Mol Sci. 2022;23:4334.
35. Heymann F, Tacke F. Immunology in the liver - from homeostasis to disease. Nat Rev Gastroenterol Hepatol. 2016;13:88-110.
36. Zhang X, Fan L, Wu J, et al. Macrophage p38α promotes nutritional steatohepatitis through M1 polarization. J Hepatol. 2019;71:163-74.
37. Zhang X, Han J, Man K, et al. CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy. J Hepatol. 2016;64:160-70.
38. Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol. 2017;17:306-21.
39. Grunhut J, Wang W, Aykut B, et al. Macrophages in nonalcoholic steatohepatitis: friend or foe? Eur Med J Hepatol. 2018;6:100-9.
40. Wang F, Zhang X, Liu W, et al. Activated natural killer cell promotes nonalcoholic steatohepatitis through mediating JAK/STAT pathway. Cell Mol Gastroenterol Hepatol. 2022;13:257-74.
41. Jorch SK, Kubes P. An emerging role for neutrophil extracellular traps in noninfectious disease. Nat Med. 2017;23:279-87.
42. Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol. 2022;22:429-43.
43. Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014;46:352-6.
44. Eslam M, George J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat Rev Gastroenterol Hepatol. 2019;17:40-52.
45. Luukkonen PK, Qadri S, Ahlholm N, et al. Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease. J Hepatol. 2022;76:526-35.
47. Pei Y, Goh GB. Genetic risk factors for metabolic dysfunction-associated steatotic liver disease. Gut Liver. 2025;19:8-18.
48. BasuRay S, Wang Y, Smagris E, Cohen JC, Hobbs HH. Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. Proc Natl Acad Sci U S A. 2019;116:9521-6.
49. Li JZ, Huang Y, Karaman R, et al. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J Clin Invest. 2012;122:4130-44.
50. Kabbani M, Michailidis E, Steensels S, et al. Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice. Cell Rep. 2022;40:111321.
51. Basuray S, Smagris E, Cohen JC, Hobbs HH. The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation. Hepatology. 2017;66:1111-24.
52. Wang Y, Kory N, Basuray S, Cohen JC, Hobbs HH. PNPLA3, CGI‐58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice. Hepatology. 2019;69:2427-41.
53. Cherubini A, Ostadreza M, Jamialahmadi O, et al. ; EPIDEMIC Study Investigators. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women. Nat Med. 2023;29:2643-55.
54. Yuan S, Liu H, Yuan D, et al. PNPLA3 I148M mediates the regulatory effect of NF‐kB on inflammation in PA‐treated HepG2 cells. J Cell Mol Med. 2019;24:1541-52.
55. Banini BA, Kumar DP, Cazanave S, et al. Identification of a metabolic, transcriptomic, and molecular signature of Patatin-like phospholipase domain containing 3-mediated acceleration of steatohepatitis. Hepatology. 2021;73:1290-306.
56. Luukkonen PK, Porthan K, Ahlholm N, et al. The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans. Cell Metab. 2023;35:1887-96.e5.
57. Boeckmans J, Gatzios A, Schattenberg JM, Koek GH, Rodrigues RM, Vanhaecke T. PNPLA3 I148M and response to treatment for hepatic steatosis: a systematic review. Liver Int. 2023;43:975-88.
58. Luukkonen PK, Sakuma I, Gaspar RC, et al. Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis. Proc Natl Acad Sci U S A. 2023;120:e2217543120.
59. Luukkonen PK, Tukiainen T, Juuti A, et al. Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease. JCI Insight. 2020;5:e132158.
60. Verweij N, Haas ME, Nielsen JB, et al. Germline Mutations in CIDEB and Protection against Liver Disease. N Engl J Med. 2022;387:332-44.
61. Lee HA, Kim HY. Therapeutic mechanisms and clinical effects of glucagon-like peptide 1 receptor agonists in nonalcoholic fatty liver disease. Int J Mol Sci. 2023;24:9324.
62. Yabut JM, Drucker DJ. Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease. Endocr Rev. 2023;44:14-32.
63. Armstrong MJ, Gaunt P, Aithal GP, et al.; LEAN trial team. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679-90.
64. Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6:275-86.
65. Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113-24.
66. Loomba R, Abdelmalek MF, Armstrong MJ, et al. ; NN9931-4492 investigators. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:511-22.
67. Armstrong MJ, Okanoue T, Sundby Palle M, Sejling AS, Tawfik M, Roden M. Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: post hoc analysis of three randomised controlled trials. Diabetes Obes Metab. 2025;27:710-8.
68. Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites. 2021;11:73.
69. Sanyal AJ, Newsome PN, Kliers I, et al. ; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089-99.
71. Deacon CF, Nauck MA, Meier J, Hücking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab. 2000;85:3575-81.
72. Genua I, Cusi K. Pharmacological approaches to nonalcoholic fatty liver disease: current and future therapies. Diabetes Spectr. 2024;37:48-58.
73. Frías JP, Davies MJ, Rosenstock J, et al. ; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503-15.
74. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-16.
75. Hartman ML, Sanyal AJ, Loomba R, et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care. 2020;43:1352-5.
76. Loomba R, Hartman ML, Lawitz EJ, et al. ; SYNERGY-NASH Investigators. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391:299-310.
77. Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10:393-406.
78. Perry RJ, Zhang D, Guerra MT, et al. Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis. Nature. 2020;579:279-83.
79. Kim T, Nason S, Holleman C, et al. Glucagon receptor signaling regulates energy metabolism via hepatic farnesoid X receptor and fibroblast growth factor 21. Diabetes. 2018;67:1773-82.
80. Lv S, Qiu X, Li J, et al. Glucagon-induced extracellular cAMP regulates hepatic lipid metabolism. J Endocrinol. 2017;234:73-87.
81. Romero-Gómez M, Lawitz E, Shankar RR, et al. ; MK-6024 P001 Study Group. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. J Hepatol. 2023;79:888-97.
82. le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12:162-73.
83. Sanyal AJ, Bedossa P, Fraessdorf M, et al. ; 1404-0043 Trial Investigators. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391:311-9.
84. Noureddin M, Harrison SA, Loomba R, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet. 2025;406:2644-55.
86. Armstrong MJ, Hull D, Guo K, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol. 2016;64:399-408.
87. Petrovic A, Igrec D, Rozac K, et al. The role of GLP1-RAs in direct modulation of lipid metabolism in hepatic tissue as determined using in vitro models of NAFLD. Curr Issues Mol Biol. 2023;45:4544-56.
88. Memel Z, Gold SL, Pearlman M, Muratore A, Martindale R. Impact of GLP-1 receptor agonist therapy in patients high risk for sarcopenia. Curr Nutr Rep. 2025;14:63.
89. Chiang CH, Jaroenlapnopparat A, Colak SC, et al. Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis. Gastroenterology. 2025;169:1268-81.
90. Pasternak B, Wintzell V, Hviid A, et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2024;385:e078225.
91. Jeong C, Han N, Jeon N, et al. Efficacy and safety of fibroblast growth factor‐21 analogs for the treatment of metabolic dysfunction‐associated steatohepatitis: a systematic review and meta‐analysis. Clin Pharmacol Ther. 2024;116:72-81.
92. Alkhouri N, Loomba R, Frias JP, et al. Pegozafermin led to significant metabolic benefits, in addition to robust beneficial effects on the liver, in an open-label cohort of a phase 1b/2a study in subjects with non-alcoholic steatohepatitis (NASH). Metabolism. 2023;142:155455. Available from: https://www.metabolismjournal.com/article/S0026-0495(23)00058-6/abstract. [Last accessed on 25 May 2026].
93. Kamrul-Hasan ABM, Borozan S, Jena S, et al. Safety and efficacy of efruxifermin in metabolic dysfunction-associated steatohepatitis: a systematic review. World J Gastrointest Pharmacol Ther. 2025;16:110709.
94. Longo M, Paolini E, Di Benedetto P, Tomassini E, Meroni M, Dongiovanni P. DGAT1 and DGAT2 inhibitors for metabolic dysfunction-associated steatotic liver disease (MASLD) management: benefits for their single or combined application. Int J Mol Sci. 2024;25:9074.
95. Barb D, Kalavalapalli S, Godinez Leiva E, et al. Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD. J Hepatol. 2025;82:979-91.
96. Wang L, Berger NA, Kaelber DC, Xu R. Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with Type 2 diabetes. Gastroenterology. 2024;167:689-703.
97. Kanwal F, Kramer JR, Li L, et al. GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease. JAMA Intern Med. 2024;184:1314-23.
98. Woodard JS, Abrams GA. Increased prevalence of advanced metabolic dysfunction-associated steatotic liver disease fibrosis in type 2 diabetics despite low-risk fibrosis-4 index scores. J Endocrinol Metab. 2024;14:40-7.
99. Ebiai R, Mcnair J, Shuaibi S, et al. Unrecognized fibrosis risk in MASLD: a real-world analysis and the case for AI-Augmented stratification. Gastro Hep Adv. 2025;5:100857.
100. Yip TC, Lee HW, Lin H, et al. Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2025;83:304-14.
